Filtered By:
Specialty: Cardiology
Procedure: Angioplasty
This page shows you your search results in order of date.
Order by Relevance | Date
Total 2169 results found since Jan 2013.
Angiography-based hemodynamic features predict recurrent ischemic events after angioplasty and stenting of intracranial vertebrobasilar atherosclerotic stenosis
CONCLUSIONS: In patients with intracranial vertebrobasilar atherosclerosis treated with PTAS, preprocedural prolonged TTP of the target vessel and shortened trans-stenotic TTP difference were associated with stroke relapse. Q-DSA-defined hemodynamic parameters provided incremental predictive value over conventional parameters for stroke recurrence.CLINICAL RELEVANCE STATEMENT: Quantitative DSA analysis enables intuitive observation and semi-quantitative evaluation of peri-therapeutic cerebral blood flow. More importantly, quantitative DSA-defined hemodynamic parameters have the potential for risk stratification of patients...
Source: Atherosclerosis - September 18, 2023 Category: Cardiology Authors: Kangmo Huang Weihe Yao Mingming Zha Shanmei Qin Yingle Li Yan Xu Rui Liu Ruidong Ye Yunfei Han Wusheng Zhu Zhongzhao Teng Juan Du Xinfeng Liu Source Type: research
Polypharmacy and Bleeding Outcomes After Percutaneous Coronary Intervention
CONCLUSIONS: In a real-world population of patients undergoing PCI, approximately 90% were on ≥5 medications. Increasing number of medications was associated with a higher adjusted risk for major bleeding, but not ischemic events.PMID:37722886 | DOI:10.1253/circj.CJ-23-0558
Source: Circulation Journal - September 18, 2023 Category: Cardiology Authors: Ko Yamamoto Takeshi Morimoto Masahiro Natsuaki Hiroki Shiomi Neiko Ozasa Hiroki Sakamoto Yasuaki Takeji Takenori Domei Takeshi Tada Ryoji Taniguchi Takashi Uegaito Miho Yamada Teruki Takeda Hiroshi Eizawa Satoru Suwa Manabu Shirotani Toshihiro Tamura Mori Source Type: research
Another Step Forward in Our Ability to Predict Percutaneous Coronary Intervention Outcomes
Despite advancements in devices, technique, and patient selection, adverse events including bleeding, vascular complications, myocardial infarction, stroke, and death still occur during percutaneous coronary intervention (PCI). Accurate and up-to-date risk-adjusted models that predict mortality after PCI are important to inform clinical decision making, identify patient factors that increase risk, provide a standardized format to measure programmatic quality, and drive continuous quality improvement efforts to improve operator outcomes.
Source: The American Journal of Cardiology - September 18, 2023 Category: Cardiology Authors: Araba Ofosu-Somuah, Matthew A. Cavender, George A. Stouffer Tags: Editorial Source Type: research
Platelet glycoprotein IIb/IIIa inhibitor tirofiban in clopidogrel-na ïve patients undergoing elective percutaneous coronary intervention
CONCLUSION: Ad-hoc PCI in clopidogrel-naïve patients who were treated with high-dose bolus of tirofiban followed by a clopidogrel loading dose immediately after the procedure appeared to be safe.PMID:37713051 | DOI:10.1007/s12471-023-01810-2
Source: Netherlands Heart Journal - September 15, 2023 Category: Cardiology Authors: Zarina Habibi Jasper Luijkx Ben C G Gho Mustafa Ilhan Leo F Veenstra Lex A W Ruiters Mera Stein Arnoud W J van 't Hof Saman Rasoul Source Type: research
Short Versus Long Duration of Dual Antiplatelet Therapy After Second-Generation Drug-Eluting Stents Implantation in Patients with Diabetes
CONCLUSION: This meta-analysis showed no statistically significant benefit of longer DAPT over shorter DAPT therapy in patients undergoing PCI with drug-eluting stent in patients with diabetes.PMID:37713685 | DOI:10.1097/MJT.0000000000001519
Source: Atherosclerosis - September 15, 2023 Category: Cardiology Authors: Manesh Kumar Gangwani Muhammad Aziz Paul Chacko Asif Mahmood Muhammad Ali Fnu Priyanka Siraj Munir Abeer Aziz Shazib Sagheer Wade Lee-Smith Om Parkash Devesh Rai Bipul Baibhav Wilbert S Aronow Source Type: research
Platelet glycoprotein IIb/IIIa inhibitor tirofiban in clopidogrel-na ïve patients undergoing elective percutaneous coronary intervention
CONCLUSION: Ad-hoc PCI in clopidogrel-naïve patients who were treated with high-dose bolus of tirofiban followed by a clopidogrel loading dose immediately after the procedure appeared to be safe.PMID:37713051 | DOI:10.1007/s12471-023-01810-2
Source: Netherlands Heart Journal - September 15, 2023 Category: Cardiology Authors: Zarina Habibi Jasper Luijkx Ben C G Gho Mustafa Ilhan Leo F Veenstra Lex A W Ruiters Mera Stein Arnoud W J van 't Hof Saman Rasoul Source Type: research
Short Versus Long Duration of Dual Antiplatelet Therapy After Second-Generation Drug-Eluting Stents Implantation in Patients with Diabetes
CONCLUSION: This meta-analysis showed no statistically significant benefit of longer DAPT over shorter DAPT therapy in patients undergoing PCI with drug-eluting stent in patients with diabetes.PMID:37713685 | DOI:10.1097/MJT.0000000000001519
Source: Atherosclerosis - September 15, 2023 Category: Cardiology Authors: Manesh Kumar Gangwani Muhammad Aziz Paul Chacko Asif Mahmood Muhammad Ali Fnu Priyanka Siraj Munir Abeer Aziz Shazib Sagheer Wade Lee-Smith Om Parkash Devesh Rai Bipul Baibhav Wilbert S Aronow Source Type: research
Platelet glycoprotein IIb/IIIa inhibitor tirofiban in clopidogrel-na ïve patients undergoing elective percutaneous coronary intervention
CONCLUSION: Ad-hoc PCI in clopidogrel-naïve patients who were treated with high-dose bolus of tirofiban followed by a clopidogrel loading dose immediately after the procedure appeared to be safe.PMID:37713051 | DOI:10.1007/s12471-023-01810-2
Source: Netherlands Heart Journal - September 15, 2023 Category: Cardiology Authors: Zarina Habibi Jasper Luijkx Ben C G Gho Mustafa Ilhan Leo F Veenstra Lex A W Ruiters Mera Stein Arnoud W J van 't Hof Saman Rasoul Source Type: research
Temporal trends of case-fatality in patients undergoing dual-injection coronary chronic total occlusion recanalization
ConclusionAnnual number of CTO procedures performed in Germany increased from 2009 to 2020 with a concomitant anti-proportional decrease in the case-fatality. Our findings may help to draw more attention to predictors of in-hospital case fatality in patients hospitalized for CTO recanalization.Graphical abstract
Source: Clinical Research in Cardiology - September 11, 2023 Category: Cardiology Source Type: research
Boston Scientific Announces FDA Approval for the Latest-Generation WATCHMAN FLX ™ Pro Left Atrial Appendage Closure Device
Designed to further advance the procedural performance and safety of the WATCHMAN technology, which is indicated to reduce stroke risk in patients with non-valvular atrial fibrillation (NVAF) who need an alternative to oral anticoagulation therapy, the device now features a polymer coating, visualization markers and a broader size matrix to treat a wider range of patients.
Source: News from Angioplasty.Org - September 8, 2023 Category: Cardiology Source Type: news
